JP2024519629A5 - - Google Patents
Info
- Publication number
- JP2024519629A5 JP2024519629A5 JP2023513604A JP2023513604A JP2024519629A5 JP 2024519629 A5 JP2024519629 A5 JP 2024519629A5 JP 2023513604 A JP2023513604 A JP 2023513604A JP 2023513604 A JP2023513604 A JP 2023513604A JP 2024519629 A5 JP2024519629 A5 JP 2024519629A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- weeks
- dose
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163189541P | 2021-05-17 | 2021-05-17 | |
| US63/189,541 | 2021-05-17 | ||
| US202163235398P | 2021-08-20 | 2021-08-20 | |
| US63/235,398 | 2021-08-20 | ||
| US202263297420P | 2022-01-07 | 2022-01-07 | |
| US63/297,420 | 2022-01-07 | ||
| US202263306315P | 2022-02-03 | 2022-02-03 | |
| US63/306,315 | 2022-02-03 | ||
| PCT/US2022/029462 WO2022245739A1 (en) | 2021-05-17 | 2022-05-16 | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519629A JP2024519629A (ja) | 2024-05-21 |
| JP2024519629A5 true JP2024519629A5 (https=) | 2025-05-23 |
Family
ID=81975181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513604A Pending JP2024519629A (ja) | 2021-05-17 | 2022-05-16 | 血管新生性眼疾患の治療のための長期の高用量ｖｅｇｆアンタゴニストレジメン |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20230302085A1 (https=) |
| EP (2) | EP4647125A3 (https=) |
| JP (1) | JP2024519629A (https=) |
| KR (1) | KR20240008821A (https=) |
| AU (2) | AU2022275786C1 (https=) |
| BR (1) | BR112023023002A2 (https=) |
| CA (1) | CA3190663A1 (https=) |
| CL (3) | CL2023003396A1 (https=) |
| DK (1) | DK4185318T3 (https=) |
| ES (1) | ES3041647T3 (https=) |
| FI (1) | FI4185318T3 (https=) |
| HR (1) | HRP20251282T8 (https=) |
| IL (1) | IL308505A (https=) |
| JO (1) | JOP20230283A1 (https=) |
| LT (1) | LT4185318T (https=) |
| MX (1) | MX2023013554A (https=) |
| PE (1) | PE20240922A1 (https=) |
| PL (1) | PL4185318T3 (https=) |
| PT (1) | PT4185318T (https=) |
| RS (1) | RS67369B1 (https=) |
| SI (1) | SI4185318T1 (https=) |
| TW (1) | TW202313095A (https=) |
| WO (1) | WO2022245739A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| IL315347A (en) * | 2022-03-15 | 2024-11-01 | Regeneron Pharma | Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders |
| IL315374A (en) * | 2022-03-15 | 2024-11-01 | Regeneron Pharma | Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN121712520A (zh) * | 2023-06-23 | 2026-03-20 | 瑞泽恩制药公司 | 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 |
| US20260055171A1 (en) | 2024-06-11 | 2026-02-26 | Regeneron Pharmaceuticals, Inc. | Vegf antagonists and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| EP1767546B1 (en) | 2004-06-08 | 2012-03-07 | Chengdu Kanghong Biotechnologies Co., Ltd. | Angiogenesis-inhibiting chimeric protein and the use |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| KR20190049934A (ko) * | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| AU2012212047A1 (en) * | 2011-02-03 | 2013-08-22 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| CA3010862A1 (en) * | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
| HUE059827T2 (hu) * | 2017-11-30 | 2023-01-28 | Regeneron Pharma | VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére |
| CN117138171A (zh) | 2017-12-13 | 2023-12-01 | 里珍纳龙药品有限公司 | 用于精确剂量输送的装置和方法 |
| DK4364724T3 (da) * | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| US20220306732A1 (en) * | 2019-09-12 | 2022-09-29 | Lupin Limited | Modified dosing of vegf inhibitors for ophthalmic use |
-
2022
- 2022-05-16 KR KR1020237013896A patent/KR20240008821A/ko active Pending
- 2022-05-16 IL IL308505A patent/IL308505A/en unknown
- 2022-05-16 US US18/021,802 patent/US20230302085A1/en active Pending
- 2022-05-16 JP JP2023513604A patent/JP2024519629A/ja active Pending
- 2022-05-16 TW TW111118217A patent/TW202313095A/zh unknown
- 2022-05-16 MX MX2023013554A patent/MX2023013554A/es unknown
- 2022-05-16 BR BR112023023002A patent/BR112023023002A2/pt unknown
- 2022-05-16 EP EP25189523.1A patent/EP4647125A3/en active Pending
- 2022-05-16 PE PE2023003023A patent/PE20240922A1/es unknown
- 2022-05-16 PT PT227287240T patent/PT4185318T/pt unknown
- 2022-05-16 ES ES22728724T patent/ES3041647T3/es active Active
- 2022-05-16 EP EP22728724.0A patent/EP4185318B1/en active Active
- 2022-05-16 SI SI202230175T patent/SI4185318T1/sl unknown
- 2022-05-16 WO PCT/US2022/029462 patent/WO2022245739A1/en not_active Ceased
- 2022-05-16 RS RS20251029A patent/RS67369B1/sr unknown
- 2022-05-16 DK DK22728724.0T patent/DK4185318T3/da active
- 2022-05-16 CA CA3190663A patent/CA3190663A1/en active Pending
- 2022-05-16 AU AU2022275786A patent/AU2022275786C1/en active Active
- 2022-05-16 LT LTEPPCT/US2022/029462T patent/LT4185318T/lt unknown
- 2022-05-16 HR HRP20251282TT patent/HRP20251282T8/hr unknown
- 2022-05-16 PL PL22728724.0T patent/PL4185318T3/pl unknown
- 2022-05-16 FI FIEP22728724.0T patent/FI4185318T3/fi active
-
2023
- 2023-11-06 JO JOJO/P/2023/0283A patent/JOP20230283A1/ar unknown
- 2023-11-14 CL CL2023003396A patent/CL2023003396A1/es unknown
-
2024
- 2024-10-02 CL CL2024002972A patent/CL2024002972A1/es unknown
-
2025
- 2025-04-29 CL CL2025001269A patent/CL2025001269A1/es unknown
- 2025-09-04 AU AU2025226774A patent/AU2025226774A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024519629A5 (https=) | ||
| Samanta et al. | Emerging therapies in neovascular age-related macular degeneration in 2020 | |
| JP2023071798A5 (https=) | ||
| JP2023099094A5 (https=) | ||
| FI4364724T3 (fi) | Korkean pitoisuuden VEGF-reseptorifuusioproteiinia sisältäviä formulaatioita | |
| JP2025084976A5 (https=) | ||
| US11052130B2 (en) | Method for treating eye diseases with a fusion protein of a tissue-penetrating peptide and anti-vascular endothelial growth factor | |
| FI4185318T3 (fi) | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon | |
| CN109715189B (zh) | 靶向VE-PTP(HPTP-β)的人源化单克隆抗体 | |
| CA3025258C (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| JP2017061467A5 (https=) | ||
| CN103533950A (zh) | Vegf拮抗剂在治疗血管生成眼病中的用途 | |
| WO2014203183A1 (en) | Use of a vegf antagonist in treating macular edema | |
| US11944663B2 (en) | Method for treating angiogenic eye disorders using VEGF antagonists | |
| US20130004486A1 (en) | Treatment of vascularized pigment epithelial detachment with anti-vegf therapy | |
| Sawada et al. | Retinal vein occlusion | |
| JP7828274B2 (ja) | 眼疾患を治療するための方法 | |
| CN116710137A (zh) | 用于在治疗眼部疾病的方法中使用的vegf拮抗剂 | |
| TW202237181A (zh) | 治療眼部疾病之方法 | |
| Khandelwal et al. | Exploring the Therapeutic Potential of Anti-VEGF Drugs for the Management of Diabetic Retinopathy: An Overview | |
| Chan | Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting. Baltimore, Maryland, USA-May 7-11, 2017 | |
| WO2025061000A1 (zh) | 一种用于治疗受试者中与血管新生相关的眼病的方法 | |
| El Hatew | Recent Trends of Antiangiogenic Drugs in Ophthalmology | |
| CN120965891A (zh) | 同时靶向bmp-2与vegf-a的双特异性抗体融合蛋白及其在制备糖尿病视网膜病变治疗药物中的应用 | |
| HK40121539A (zh) | 使用抗fcrn抗体治疗慢性炎性脱髓鞘性多发性神经病的方法 |